

Lung Cancer and Head & Neck Cancer: Comprehensive Review and Update

Saturday, August 14, 2010, Pasadena, CA

7:30 am - 2:35 pm

Sheraton Pasadena, 303 Cordova Street, Pasadena, CA 91101

Phone: (626) 449-4000

Program Director

Chandra P. Belani, MD

Hershey, PA

Statement of Need/Program Overview

This program is intended to facilitate interaction among oncologists and nurses interested in development of novel therapeutics for treatment of lung cancer and head & neck cancer. In addition to multimodality therapy, adjuvant therapy, this symposium will present data of most promising emerging agents currently in development for the treatment of lung cancer and head & neck cancer. There will be in-depth discussion of both antiangiogenic agents and inhibitors of EGFR pathways. Drugs that target multiple signaling pathways will also be given significant focus.

Target Audience:

This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, pharmacists, and registered oncology nurses interested in new developments for treatment of lung cancer and head & neck cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows are also invited to attend.

PHYSICIAN CONTINUING EDUCATION

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System and International Cancer Network. A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

A. Webb Roberts Center for CME of Baylor Health Care System designates this educational activity for a maximum of 5.0 *AMA PRA Category 1 Credit(s)*TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

NURSING ACCREDITATION STATEMENT

TNA/ANCC

Accreditation Statement

Camena Group, Inc. is approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation

CREDIT DESIGNATION

This educational activity for 5.0 contact hours is provided by Camena Group, Inc

A statement of credit will be issued only upon receipt of a completed activity evaluation form, and will be mailed within six weeks.

EDUCATIONAL GRANTS

This activity is supported by education grants from:

Genentech BioOncology

Lilly USA, LLC

Jointly Sponsored by



First Name _____ Middle Initial _____ Last Name _____

Physician Pa-C Fellow NP PhD Pharmacist Industry Nurse Other

Specialty _____

Mailing Address _____

City _____ State _____ Zip Code _____

Phone _____ Fax _____ E-Mail _____

Registration Fee

Registration fee partially covers continental breakfast, lunch and syllabus book

Physicians \$100.00 Nurses, Pharmacists, others \$50.00

Fellows \$50.00 *Industry \$350.00

*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Payment may be made: MC Visa Discover Amex Check

Credit Card Number _____ Expiration Date _____ Security code (AmEx on front) _____

Name and address* as it appears on Credit Card _____

Signature _____

*as given on monthly credit card statement

Register online at www.Internationalcancernetwork.com

Please make checks payable to International Cancer Network. Mail checks to 860 Hebron Pkwy, Ste 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. If you have any questions please call 972-939-6206 or

E-mail: knaidu@internationalcancernetwork.com

If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.

Fax registration to:
443-267-0016

Mail registration to:
860 Hebron Pkwy, Ste 1104,
Lewisville, TX 75057

Lung Cancer and Head & Neck Cancer: Comprehensive Review and Update

Saturday, August 14, 2010, Pasadena, CA - 7:30 am - 2:35 pm

AGENDA

7:30 AM BREAKFAST

8:25 AM Welcome and Introductions

Chandra P. Belani, MD

Adjuvant Therapy and Multimodality Therapy for Lung Cancer

Session Chair and Moderator: Chandra P. Belani, MD

8:30 AM State of the Art and Integration of Novel Agents in the Treatment of Lung Cancer

Heather Wakelee, MD

8:55 AM Early Stage Non-Small-cell Lung Cancer: Adjuvant and Neoadjuvant Therapy

David Jablons, MD

9:20 AM Management of Stage III Disease: Multimodality Therapy

Hak Choy, MD

9:45 AM Panel Discussion and Case Presentations

Heather Wakelee, MD; David Jablons, MD; Hak Choy, MD

10:05 AM BREAK

Targeting VEGF and EGFR Receptors in Lung Cancer

Session Chair and Moderator: Suresh Ramalingam, MD

10:15 AM State of the Art of Targeting VEGF Receptors in Lung Cancer

Ronald Natale, MD

10:40 AM EGFR Inhibitors-Optimal Usage & Biomarkers for Patient Selection

Suresh Ramalingam, MD

Novel Treatment Options for Lung Cancer and Head & Neck Cancers

Session Chair and Moderator: Chandra P. Belani, MD

11:05 AM Role of Maintenance Therapy in Lung Cancer - Debate (Pro)

Chandra P. Belani, MD

11:30 AM Role of Maintenance Therapy in Lung Cancer - Debate (Con)

Afshin Dowlati, MD

11:55 AM Panel Discussion and Case Presentations

Ronald Natale, MD; Suresh Ramalingam, MD

Chandra P. Belani, MD; Afshin Dowlati, MD

12:15 PM LUNCH

1:00 PM Current strategies in the Treatment of Head & Neck Cancers

Ezra Cohen, MD

1:25 PM Second-line Treatment Options for Lung Cancer

Shirish Gadgeel, MD

1:50 PM Novel Agents for Small-Cell and Non-Small-Cell Lung Cancer: HDAC Inhibitors, Nab-Paclitaxel, IGF-1R targeted agents, Hedgehog inhibitors, met Inhibitors

Patricia LoRusso, MD

2:15 PM Panel Discussion and Case Presentations

Ezra Cohen, MD; Shirish Gadgeel, MD

Patricia LoRusso, MD

2:35 PM Closing Remarks & Adjourn

Chandra P. Belani, MD

For online registration and more information visit: www.InternationalCancerNetwork.com

If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.